Intra-operative Uterosacral Ligament Bupivacaine Injection During Minimally Invasive Hysterectomy
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is proof of concept, phase I randomized controlled trial studying a short acting
non-opioid anesthetic, bupivacaine to improve post-operative pain in gynecologic surgery
patients. Patients who are undergoing minimally invasive (laparoscopic or robotic)
hysterectomy will be randomized to receive no uterosacral injection, normal saline
uterosacral injection, or 0.25% bupivacaine uterosacral injection just prior to colpotomy
(incision around the cervix and removal of uterus) during minimally invasive hysterectomy.